Format

Send to

Choose Destination
Thromb Haemost. 2011 Nov;106(5):849-57. doi: 10.1160/TH11-05-0330. Epub 2011 Oct 6.

The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.

Author information

1
Department of Pathology,Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Abstract

Rheumatic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), are associated with antibodies to "self" antigens. Persons with autoimmune diseases, most notably SLE, are at increased risk for developing accelerated cardiovascular disease. The link between immune and inflammatory responses in the pathogenesis of cardiovascular disease has been firmly established; yet, despite our increasing knowledge, accelerated atherosclerosis continues to be a significant co-morbidity and cause of mortality in SLE. Recent animal models have been generated in order to identify mechanism(s) behind SLE-accelerated atherosclerosis. In addition, clinical studies have been designed to examine potential treatments options. This review will highlight data from recent studies of immunity in SLE and atherosclerosis and discuss the potential implications of these investigations.

PMID:
21979131
PMCID:
PMC3306215
DOI:
10.1160/TH11-05-0330
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
Loading ...
Support Center